Bristol-Myers Squibb. has filed a patent for a method of treating cutaneous lupus erythematosus. The method involves administering a TLR7 inhibitor along with either prednisolone or hydroxychloroquine to the patient. This combination aims to provide a therapeutically effective treatment for the condition. GlobalData’s report on Bristol-Myers Squibb gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Bristol-Myers Squibb, Cancer treatment biomarkers was a key innovation area identified from patents. Bristol-Myers Squibb's grant share as of September 2023 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
Method of treating cutaneous lupus erythematosus with tlr7 inhibitor
A recently filed patent (Publication Number: US20230310408A1) describes a method for treating patients with cutaneous lupus erythematosus. The method involves administering a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof.
The patent claims specify various aspects of the method. The TLR7 inhibitor can be any suitable compound, although the specific inhibitor is not mentioned in the claims. The method can involve administering the TLR7 inhibitor in combination with prednisolone or hydroxychloroquine, or both. The therapeutically effective doses of the TLR7 inhibitor, prednisolone, and hydroxychloroquine range from 0.1 to 100 mg per day, 0.5 to 50 mg per day, and 1 to 20 mg per day, respectively.
The claims also describe different administration methods. The TLR7 inhibitor and the second agent can be administered concurrently, sequentially, or with one administered prior to the other. The claims provide specific dosage ranges for each combination.
In summary, the filed patent proposes a method for treating cutaneous lupus erythematosus by administering a TLR7 inhibitor in combination with prednisolone and/or hydroxychloroquine. The patent claims cover various aspects of the method, including the specific doses of each component and different administration methods. This method has the potential to provide a new treatment option for patients with cutaneous lupus erythematosus, although further research and clinical trials may be necessary to validate its efficacy and safety.
To know more about GlobalData’s detailed insights on Bristol-Myers Squibb, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
